Publications - '5'

Publications 1 - 9 de 9
| % | ( | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | < | ? | A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | [ | ` | {
Titre DOI
5-Amino-6,7,8,9-Tetrahydrobenzo[b][1,8]Naphthyridin-2(1H)-One: The first Example of a new Family of HuperTacrines for Alzheimer's Disease Therapy
A. Balmori; M. Chioua; R.Puig de la Bellacasa; R. Estrada-Tejedor; L. Ismaili; J. Marco-Contelles; J.I. Borrell
2017 		10.1002/slct.201700289
5-fluorouracil plus bevacizumab plus anakinra for patients with metastatic colorectal cancer refractory to standard therapies (IRAFU): An investigator-initiated, open-label, single-arm, multicentre, phase 2 study.
N. Isambert; A. Hervieu; A. Hennequin; C. Borg; C. Rebe; V. Derangere; C. Richard; J. Blanc; A. Bertaut; F. Ghiringhelli
2018 		10.1200/JCO.2018.36.15_suppl.e15540
5-fluorouracil therapeutic drug monitoring: Update and recommendations of the STP-PT group of the SFPT and the GPCO-Unicancer
F. Lemaitre; F. Goirand; M. Launay; E. Chatelut; J.C. Boyer; A. Evrard; M.N. Paludetto; R. Guilhaumou; J. Ciccolini; A. Schmitt
2018 		10.1016/j.bulcan.2018.06.008
5-year follow-up of spinal and sacroiliac MRI abnormalities in early axial spondyloarthritis: data from the DESIR cohort
Q. Madari; A. Sepriano; S. Ramiro; A. Molto; P. Claudepierre; D. Wendling; M. Dougados; D. van der Heijde; F.A. Van Gaalen
2020 		10.1136/rmdopen-2019-001093
5-year follow-up of the safety, tolerability and efficacy of subcutaneous trastuzumab for the adjuvant treatment of HER2-positive early breast cancer. Results from the SafeHER Phase III trial
J. Gligorov; X. Pivot; B. Ataseven; M. De Laurentiis; A. Llombart; K.H. Jung; A. Manikhas; H.A. Azim; A. Alexandrou; K. Gupta; L. Herraez-Baranda; N. Tosti; E. Restuccia
2021
5-year follow-up of the safety, tolerability and efficacy of subcutaneous trastuzumab for the adjuvant treatment of HER2-positive early breast cancer. Results from the SafeHER Phase III trial
J. Gligorov; X. Pivot; B. Ataseven; M. De Laurentiis; A. Llombart; K.H. Jung; A. Manikhas; H.A. Azim; A. Alexandrou; K. Gupta; L. Herraez-Baranda; N. Tosti; E. Restuccia
2021
5-YEAR OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL IN MULTIPLE MYELOMA BY LINE OF TREATMENT FROM THE FRENCH HEMATOLOGIC MALIGNANCY REGISTRY
M. Mounier; S. Gauthier; Mayandi; X. Troussard; A. Monnereau; C. Guilhaume; F. Suzan; C. Blachier-Poisson; N. Despiegel
2016 		10.1016/j.jval.2016.09.2374
5-year overall survival of early breast cancer during pregnancy: A multicenter French case control study
L. Vanlemmens; A. Ploquin; S. Delaloge; R. Rouzier; A. Lesur; J.S. Frenel; C. Loustalot; T. Bachelot; M. Provansal; J.M. Ferrero; F. Coussy; M. Debled; P. Kerbrat; A. Vinceneux; A. Djelila; M. Baron; S. Jebert; E. Decoupigny; E. Tresch; J. Bonneterre
2016 		10.1158/1538-7445.SABCS15-P1-07-02
5azadC treatment upregulates miR-375 level and represses HPV16 E6 expression
A. Morel; A. Baguet; J. Perrard; C. Demeret; E. Jacquin; D. Guenat; C. Mougin; J.L. Pretet
2017 		10.18632/oncotarget.17575